Chugai Pharmaceutical Co., Ltd.
CHGCF
$42.03
-$1.06-2.45%
OTC PK
| 06/30/2026 | 12/31/2025 | 06/30/2025 | 03/31/2025 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 1.70B | 1.84B | 1.74B | 1.70B | 1.38B |
| Total Other Revenue | 411.96M | 409.33M | 265.09M | 188.57M | 218.73M |
| Total Revenue | 2.11B | 2.25B | 2.01B | 1.89B | 1.60B |
| Cost of Revenue | 643.94M | 568.15M | 609.76M | 576.28M | 491.44M |
| Gross Profit | 1.47B | 1.68B | 1.40B | 1.32B | 1.10B |
| SG&A Expenses | 179.46M | 239.60M | 196.71M | 152.48M | 152.15M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -1.80M | 2.63M | -61.14M | -1.17M | 1.25M |
| Total Operating Expenses | 1.12B | 1.15B | 1.06B | 996.14M | 923.43M |
| Operating Income | 993.90M | 1.10B | 946.41M | 896.67M | 672.81M |
| Income Before Tax | 1.04B | 1.10B | 941.63M | 891.28M | 672.91M |
| Income Tax Expenses | 325.58M | 269.25M | 268.96M | 253.25M | 171.70M |
| Earnings from Continuing Operations | 718.78M | 833.22M | 672.67M | 638.03M | 501.21M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 718.78M | 833.22M | 672.67M | 638.03M | 501.21M |
| EBIT | 993.90M | 1.10B | 946.41M | 896.67M | 672.81M |
| EBITDA | 998.23M | 1.30B | 949.18M | 899.30M | 675.50M |
| EPS Basic | 0.44 | 0.51 | 0.41 | 0.39 | 0.30 |
| Normalized Basic EPS | 0.40 | 0.42 | 0.36 | -- | 0.26 |
| EPS Diluted | 0.44 | 0.51 | 0.41 | 0.39 | 0.30 |
| Normalized Diluted EPS | 0.40 | 0.42 | 0.36 | -- | 0.26 |
| Average Basic Shares Outstanding | 1.65B | 1.65B | 1.65B | 1.65B | 1.65B |
| Average Diluted Shares Outstanding | 1.65B | 1.65B | 1.65B | 1.65B | 1.65B |
| Dividend Per Share | -- | 0.47 | 0.35 | -- | -- |
| Payout Ratio | -- | -- | 0.45% | -- | 87.31% |